Acquisition Momentum Allergan acquired Bonti in 2018 for $195M after a 2015 Series A, signaling strong corporate appetite for next generation neurotoxin platforms and creating licensing or co development sales opportunities with big pharma or cosmetics incumbents.

Lead Asset Validation Lead product EB-001 delivered proof of concept results in 2017, indicating a viable platform with potential for strategic partnerships or licensing to broaden indications and speed to market.

Neurotoxin Opportunity Bonti's proprietary platform targets next generation neurotoxins for unmet indications, placing it in a market class where cosmetic and therapeutic neurotoxins are actively pursued by large players seeking novel entrants and new mechanisms.

Lean BD A lean team implies a preference for external collaborations, licensing deals, and CRO CMOs to accelerate development and commercial reach.

Competitive Positioning Regional access to dermatology networks through Newport Beach location supports partnerships with clinics, distributors, and manufacturers to pursue opportunities against competitors in the neurotoxin space.